Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: Systematic review

European Journal of Cancer Prevention

Volumn 21, Issue 1, 2012, Pages 73-81

  Rebolj, Matejka ^a   Njor, Sisse H ^a   Lynge, Elsebeth ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Age groups; Cervical cancer; Cytology; Early detection of cancer; Human papillomavirus DNA probes

Indexed keywords

VIRUS DNA;

CANCER SCREENING; CYTOLOGY; DNA DETERMINATION; FALSE POSITIVE RESULT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

DNA, VIRAL; FEMALE; GENETIC TESTING; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 82555191377     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283498dbe     Document Type: Review

References (38)

1. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, et al. (2010). Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 340:1-8.
2. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. (2008). Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337:798-80.
3. BC Cancer Agency. 2011. HPV FOCAL study: investigative team. Available at: http://www.bccancer.bc.ca/PPI/Screening/Cervical/hpvfocal/investigativeTeam/ default.htm [Accessed 3 February 2011].
4. Berkhof J, Coupe VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. (2010). The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 127:2147-2158.
5. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. (2007). Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772. (Pubitemid 350137476)
6. Castle PE (2010). Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol 7:364-365.
7. Castle PE, Katki HA (2010). Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol 11:214-215.
8. Castle PE, Schiffman M,Wheeler CM, Solomon D (2009). Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113:18-25.
9. Current Controlled Trials Ltd. 2011 Current controlled trials. Available at:http:// www.controlled-trials.com [Accessed 4 February 2011].
10. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. (2008). Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 (Suppl 10):K29-K41.
11. Davey E, Barratt A, Irwig L, Chan SF, Macaskill P, Mannes P, et al. (2006). Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367:122-132. (Pubitemid 43077128)
12. Davies P, Arbyn M, Dillner J, Kitchener HC, Meijer CJ, Ronco G, et al. (2006). A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 118:791-796. (Pubitemid 43157653)
13. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. (2008). Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: 969-972.
14. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. (2006). Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119:2677-2684. (Pubitemid 44691325)
15. IARC (2005). IARC handbooks of cancer prevention, vol 10: cervix cancer screening. Lyon: International Agency for Research on Cancer Press.
16. IARC (2009). Biennial report 08/09. Available at: http://www.iarc.fr/en/ publications/pdfs-online/breport/breport0809/breport0809.pdf [Accessed: 3 February 2011].
17. Insinga RP, Glass AG, Myers ER, Rush BB (2007). Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 27:414-422. (Pubitemid 47106938)
18. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. (2009). ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 13:1-150.
19. Kotaniemi-Talonen L, Malila N, Nieminen P, Anttila A, Tarkkanen J, Laurila P, et al. (2008). Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 123:2902-2906.
20. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. (2009). Age-specific evaluation of primary human papillomavirus screening versus conventional cytology in a randomized setting. J Natl Cancer Inst 101:1612-1623.
21. Lynge E, Rebolj M (2009). Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 6:699-706.
22. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. (2007). Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588. (Pubitemid 47598400)
23. McGill University (2011). CCCaST - Canadian Cervical Cancer Screening Trial: investigators. Available at: http://www.mcgill.ca/cccast/investigators/ [Accessed 03 February 2011].
24. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. (2007). Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589-1597. (Pubitemid 47598401)
25. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. (2009). Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88-99.
26. Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, et al. (2010). A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 10:1-10.
27. Ostor AG (1993). Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12:186-192. (Pubitemid 23095196)
28. Rebolj M, Lynge E (2010). Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer 103:310-314.
29. Rebolj M, Pribac I, Lynge E (2011). False-positive human papillomavirus DNA tests in cervical screening: it is all in a definition. Eur J Cancer 47:255-261.
30. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. (2006a). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7:547-555. (Pubitemid 43923665)
31. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. (2006b). Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98:765-774. (Pubitemid 43983300)
32. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. (2008). Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100:492-501.
33. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del MA, et al. (2010). Efficacy of human papillomavirus testing for the detection of invasivecervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11:249-257.
34. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. (2009). HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394.
35. US National Institutes of Health (2011). ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/home [Accessed 4 February 2011].
36. van den Akker-van Marle ME, van Ballegooijen M, Rozendaal L, Meijer CJ, Habbema JD (2003). Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 89: 1830-1833. (Pubitemid 37533254)
37. van Oortmarssen GJ, Habbema JD (1991). Epidemiological evidence for agedependent regression of pre-invasive cervical cancer. Br J Cancer 64: 559-565.
38. Wardle J, Pope R (1992). The psychological costs of screening for cancer. J Psychosom Res 36:609-624.